IL33: Interleukin-33
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells.
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on IL33, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 3
| Itepekimab | Phase 3 | Sanofi | Antibody | InhibitorInterleukin-33 inhibitor | 3 |
| Etokimab | Phase 2 | Anaptysbio | Antibody | Binding agentInterleukin-33 binding agent | 0 |
| Torudokimab | Phase 2 | Eli Lilly | Antibody | InhibitorInterleukin-33 inhibitor | 0 |
| An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | Itepekimab | Phase 3 | Active, not recruiting | Sanofi | Feb 20, 2026 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Itepekimab | Phase 3 | Active, not recruiting | Sanofi | Feb 19, 2025 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | Itepekimab | Phase 3 | Active, not recruiting | Sanofi | Feb 19, 2025 |
- Asthma0.73
- Allergic disease0.64
- Allergic rhinitis0.61
- Childhood onset asthma0.59
- Respiratory system disorder0.55
- Wheezing0.53
- Chronic rhinosinusitis with nasal polyps0.49
- Deep vein thrombosis0.45
- Chronic rhinosinusitis0.45
- Atopic IgE-mediated allergic disorder0.44
- Atopic eczema0.43
- Adult onset asthma0.41
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630890, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt O95760, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets